**Dupilumab treatment reduces hospitalizations in adults with moderate-to-severe atopic dermatitis: a pooled analysis of data from 7 randomized, placebo-controlled studies**

Norma P.M. Rubini¹, Jonathan I. Silverberg², Mario C. Pires³, Zhen Chen⁴, Jingdong Chao⁴, Gaëlle Bégo-Le Bagousse⁵

¹School of Medicine and Surgery, Federal University of the State of Rio de Janeiro (UNIRIO), Rio de Janeiro, Brazil; ²The George Washington University School of Medicine and Health Sciences, Washington, DC USA; ³Dermatology Service, Hospital do Servidor Público Estadual, Sao Paulo, Brazil; ⁴Regeneron Pharmaceutical, Inc., Tarrytown, NY, USA; ⁵Sanofi, Chilly Mazarin, France

**Introduction:** Patients with atopic dermatitis (AD) may require inpatient hospital treatment for refractory AD, severe AD flares (exacerbations), and infections. Dupilumab, a fully human monoclonal antibody that blocks the shared receptor component for interleukin-4 and interleukin-13, has demonstrated efficacy and was well tolerated in adults and adolescents with moderate-to-severe AD and in children aged ≥ 6 years with severe AD, in several randomized controlled trials (RCTs).

**Objectives:** To compare the rates of hospitalizations of adult patients with moderate-to-severe AD treated with dupilumab vs control by a post hoc analysis of pooled data from 7 placebo-controlled RCTs including 2,932 patients.

**Methods:** Data were analyzed from 7 placebo-controlled phase 2 or phase 3 RCTs that compared treatment with dupilumab 300 mg every 2 weeks (q2w) or weekly (qw) vs placebo for 16 or 52 weeks in adult patients with moderate-to-severe AD. 5 of these were monotherapy studies; 2 studies required use of concomitant topical corticosteroids (TCS).

**Results:** A total of 2,932 patients (1,841 dupilumab and 1,091 control) from 28 countries were included in the analysis. 77 hospitalization events were identified (31 in the dupilumab group, 46 in the control group). Patients who received dupilumab 300 mg q2w (n = 746), qw (n = 1,095), or either posology combined (“dupilumab combined”) vs control (patients receiving placebo or placebo + TCS) had lower rates of all-cause hospitalizations (5.8, 2.7, 3.8 vs 9.0 events per 100 patient-years, respectively [risk reduction 40% (p = 0.132), 73% (p < 0.001), and 61% (p < 0.001), respectively]). Dupilumab patients also had lower rates of AD-related hospitalizations (2.0, 0.4, 1.0 vs 4.1 events per 100 patient-years; [risk reduction 61% (p = 0.092), 93% (p < 0.001), and 76% (p < 0.001), respectively]). Reduced durations of the AD-related hospitalizations for patients treated with dupilumab 300 mg q2w, qw, or either posology combined vs control were also observed:10.9 (p = 0.016), 7.3 (p < 0.001), and 8.6 (p < 0.001) vs 38.9 days per 100 patient-years, respectively.

**Conclusion:** Among adults with moderate-to-severe AD, treatment with dupilumab vs control was associated with significant reductions in all-cause and AD-related hospitalization rates, and shorter duration of AD-related hospitalizations.